See more : Traumhaus AG (TRU.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Black Diamond Therapeutics, Inc. (BDTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Black Diamond Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- FirstCash Holdings, Inc (FCFS) Income Statement Analysis – Financial Results
- Earum Pharmaceuticals Limited (EARUM.BO) Income Statement Analysis – Financial Results
- Tombstone Exploration Corporation (TMBXF) Income Statement Analysis – Financial Results
- BenQ Materials Corporation (8215.TW) Income Statement Analysis – Financial Results
- Dafeng Port Heshun Technology Company Limited (8310.HK) Income Statement Analysis – Financial Results
Black Diamond Therapeutics, Inc. (BDTX)
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 437.00K | 3.24M | 2.22M | 600.00K | 47.00K | 44.00K | 24.00K |
| Gross Profit | -437.00K | -3.24M | -2.22M | -600.00K | -47.00K | -44.00K | -24.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 59.35M | 64.44M | 96.83M | 48.21M | 21.75M | 6.95M | 3.45M |
| General & Administrative | 27.11M | 28.39M | 30.04M | 21.36M | 7.58M | 1.95M | 666.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.11M | 28.39M | 30.04M | 21.36M | 7.58M | 1.95M | 666.00K |
| Other Expenses | 0.00 | -354.00K | -2.19M | -1.72M | 6.00K | -16.00K | -6.00K |
| Operating Expenses | 86.46M | 92.83M | 126.87M | 69.57M | 29.33M | 8.90M | 4.12M |
| Cost & Expenses | 86.46M | 92.83M | 126.87M | 69.57M | 29.33M | 8.90M | 4.12M |
| Interest Income | 1.92M | 2.03M | 3.46M | 4.04M | 461.00K | 4.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 1.00K | 0.00 | 0.00 | 65.00K |
| Depreciation & Amortization | 437.00K | 3.24M | 2.22M | 600.00K | 47.00K | 44.00K | 24.00K |
| EBITDA | -86.02M | -92.32M | -126.67M | -66.65M | -29.29M | -8.89M | -4.10M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -86.46M | -92.83M | -126.87M | -69.57M | -8.90M | -8.90M | -4.12M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.02M | 1.66M | 1.28M | 2.32M | -5.93M | -27.00K | -483.00K |
| Income Before Tax | -82.44M | -88.92M | -125.60M | -67.25M | -35.26M | -8.93M | -4.60M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -4.40M | -2.39M | -1.78M | 5.89M | -27.00K | 59.00K |
| Net Income | -82.44M | -84.52M | -123.20M | -65.48M | -41.14M | -8.93M | -4.60M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.88 | -2.33 | -3.40 | -1.99 | -1.15 | -0.64 | -0.64 |
| EPS Diluted | -1.88 | -2.33 | -3.40 | -1.99 | -1.15 | -0.64 | -0.64 |
| Weighted Avg Shares Out | 43.95M | 36.33M | 36.19M | 32.91M | 35.91M | 13.95M | 7.20M |
| Weighted Avg Shares Out (Dil) | 43.95M | 36.33M | 36.19M | 32.91M | 35.91M | 13.95M | 7.20M |
Black Diamond Therapeutics Announces Appointment of Oncology Clinical Development Veteran Dr. Kapil Dhingra to Board of Directors
Black Diamond Therapeutics to Present at the J.P. Morgan 39th Annual Healthcare Conference
Black Diamond Therapeutics Provides Update on GBM Program and Presents Pre-Clinical Data at the 2020 SNO Annual Meeting
Black Diamond Therapeutics to Present at the Jefferies 2020 Virtual London Healthcare Conference
Black Diamond Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Black Diamond Reports Second Quarter 2020 Results
Black Diamond Therapeutics (NASDAQ:REYN) Downgraded to “Sell” at ValuEngine
Noble Midstream Partners Reports Second-Quarter 2020 Results
U.S. IPO Week Ahead: Tax Software Leads A Diverse 7-IPO Week
Stocks To Watch: Big Focus On Big Tech
Source: https://incomestatements.info
Category: Stock Reports